Real world evidence
Impact and safety of using Bexsero in the real world across settings and target populations.2,3
Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.1
2 of 3 parents are unaware that there is a separate vaccine against meningitis B.
Some parents believe that their child may have already been protected from meningitis B with just a meningococcal conjugate (MenACWY) vaccine.4,a
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
L.K January 2021 PM-GB-BEX-WCNT-200001